Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Nurix Therapeutics (NRIX) over the last 6 years, with Q4 2025 value amounting to 0.55%.

  • Nurix Therapeutics' Return on Capital Employed fell 1200.0% to 0.55% in Q4 2025 from the same period last year, while for Nov 2025 it was 0.55%, marking a year-over-year decrease of 1200.0%. This contributed to the annual value of 0.48% for FY2025, which is 300.0% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Return on Capital Employed of 0.55% as of Q4 2025, which was down 1200.0% from 0.56% recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Return on Capital Employed high stood at 0.22% for Q2 2021, and its period low was 0.64% during Q1 2024.
  • In the last 5 years, Nurix Therapeutics' Return on Capital Employed had a median value of 0.47% in 2022 and averaged 0.46%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by -2600bps in 2022, then skyrocketed by 2200bps in 2025.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Return on Capital Employed stood at 0.28% in 2021, then tumbled by -78bps to 0.5% in 2022, then fell by -26bps to 0.63% in 2023, then soared by 32bps to 0.43% in 2024, then fell by -28bps to 0.55% in 2025.
  • Its Return on Capital Employed was 0.55% in Q4 2025, compared to 0.56% in Q3 2025 and 0.44% in Q2 2025.